Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro to Present at the 2026 Jefferies Global Healthcare Conference in London
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio Q3 EPS $(0.98) Beats $(1.26) Estimate
Kosmos Energy Shares Fall Over 10% After Q3 Earnings and Revenue Miss Forecasts
Reported Oct. 26: Korro Bio Shareholder Lynx1 Capital Management Buys 79,809 Shares At An Average Price Of $11.09/Share
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Korro to Participate in Upcoming Investor Conferences
Korro Bio Submits To Australian Alfred Health Human Ethics Committee To Start Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.